Regulation of immune-related diseases by multiple factors of chromatin, exosomes, microparticles, vaccines, oxidative stress, dormancy, protein quality control, inflammation and microenvironment: a meeting report of 2017 International Workshop of the Chinese Academy of Medical Sciences (CAMS) Initiative for Innovative Medicine on Tumor Immunology

Cui, Bing; Cao, Xuetao; Zou, Weiping; Wan, Yonghong; Wang, Ning; Wang, Yaohe; Li, Pingping; Hua, Fang; Liu, Yuying; Zhang, Xiaowei; Li, Ke; Lv, Xin; Huang, Bo; Hu, Zhuowei

doi:10.1016/j.apsb.2017.06.007

Cited by 3 publications

(2 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, challenges still exist in recognizing the coexisting targets on a tumor cell and selecting the proper epitope in TanCAR therapy 128 , 129 . In addition, oncolytic viruses can infect the host, replicate and damage certain tumor cells without harming normal cells 130 , 131 . Evidence has shown that tumor cells can be killed via the new viral proteins integrated in its cytoplasm presented by the major histocompatibility complex class I molecules, and thereafter being recognized and destroyed by CD8 T cells 130 .…”

Section: Discussionmentioning

confidence: 99%

The application of CAR-T cell therapy in hematological malignancies: advantages and challenges

Zhao

Chen

Francisco

et al. 2018

Acta Pharmaceutica Sinica B

164

143

View full text Add to dashboard Cite

Chimeric antigen receptor T cell (CAR-T cell) therapy is a novel adoptive immunotherapy where T lymphocytes are engineered with synthetic receptors known as chimeric antigen receptors (CAR). The CAR-T cell is an effector T cell that recognizes and eliminates specific cancer cells, independent of major histocompatibility complex molecules. The whole procedure of CAR-T cell production is not well understood. The CAR-T cell has been used predominantly in the treatment of hematological malignancies, including acute lymphoblastic leukemia, chronic lymphocytic leukemia, lymphoma, and multiple myeloma. Solid tumors including melanoma, breast cancer and sarcoma offer great promise in CAR-T cell research and development. CD19 CAR-T cell is most commonly used, and other targets, including CD20, CD30, CD38 and CD138 are being studied. Although this novel therapy is promising, there are several disadvantages. In this review we discuss the applications of CAR-T cells in different hematological malignancies, and pave a way for future improvement on the effectiveness and persistence of these adoptive cell therapies.

show abstract

Section: Discussionmentioning

confidence: 99%

The application of CAR-T cell therapy in hematological malignancies: advantages and challenges

Zhao

Chen

Francisco

et al. 2018

Acta Pharmaceutica Sinica B

164

143

View full text Add to dashboard Cite

show abstract

“…IL-17A is a proinflammatory cytokine produced by the Th17 subset of T-cells 1 . Th17 cells are an identified subset of T helper cells associated with chronic inflammation, autoimmune disorders, fibrotic disease, and cancer1., 2., 3., 4.. Therefore, the development of IL-17A-targeted therapeutic agents has important clinical benefits 5 .…”

Section: Introductionmentioning

confidence: 99%

Improvement in affinity and thermostability of a fully human antibody against interleukin-17A by yeast-display technology and CDR grafting

Sun

Yang

Lin

et al. 2019

Acta Pharmaceutica Sinica B

Self Cite

View full text Add to dashboard Cite

Monoclonal antibodies (mAbs) are widely used in many fields due to their high specificity and ability to recognize a broad range of antigens. IL-17A can induce a rapid inflammatory response both alone and synergistically with other proinflammatory cytokines. Accumulating evidence suggests that therapeutic intervention of IL-17A signaling offers an attractive treatment option for autoimmune diseases and cancer. Here, we present a combinatorial approach for optimizing the affinity and thermostability of a novel anti-hIL-17A antibody. From a large naïve phage-displayed library, we isolated the anti-IL-17A mAb 7H9 that can neutralize the effects of recombinant human IL-17A. However, the modest neutralization potency and poor thermostability limit its therapeutic applications. In vitro affinity optimization was then used to generate 8D3 by using yeast-displayed random mutagenesis libraries. This resulted in four key amino acid changes and provided an approximately 15-fold potency increase in a cell-based neutralization assay. Complementarity-determining regions (CDRs) of 8D3 were further grafted onto the stable framework of the huFv 4D5 to improve thermostability. The resulting hybrid antibody 9NT/S has superior stabilization and affinities beyond its original antibody. Human fibrosarcoma cell-based assays and in vivo analyses in mice indicated that the anti-IL-17A antibody 9NT/S efficiently inhibited the secretion of IL-17A-induced proinflammatory cytokines. Therefore, this lead anti-IL-17A mAb might be used as a potential best-in-class candidate for treating IL-17A related diseases.

show abstract

Highlights of the 2nd International Symposium on Tribbles and Diseases: tribbles tremble in therapeutics for immunity, metabolism, fundamental cell biology and cancer

Cui

Eyers

Dobens

et al. 2019

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

Cited by 3 publications

References 77 publications

The application of CAR-T cell therapy in hematological malignancies: advantages and challenges

The application of CAR-T cell therapy in hematological malignancies: advantages and challenges

Improvement in affinity and thermostability of a fully human antibody against interleukin-17A by yeast-display technology and CDR grafting

Highlights of the 2nd International Symposium on Tribbles and Diseases: tribbles tremble in therapeutics for immunity, metabolism, fundamental cell biology and cancer

Contact Info

Product

Resources

About